Scientific Publications utilizing SOLVO products

ABCB1/MDR1/P-gp

Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel
Kwak JO, Lee SH, Lee GS, Kim MS, Ahn YG, Lee JH, Kim SW, Kim KH, Lee MG.
Eur J Pharmacol. 2009 Nov 7.

Interaction of macrocyclic lactones with P-glycoprotein: Structure-affinity relationship
Anne Lespine, Solenne Martin, Jacques Dupuy, Alain Roulet, Thierry Pineau, Stephane Orlowski, Michel Alvinerie
European journal of pharmaceutical sciences 30 (2007) 84-94

Inhibition of the MDR1 transporter by new phenothiazine derivatives
Attila Konya, Attila Andor, Peter Satorhelyi, Klara Nemeth, Istvan Kurucz
Biochemical and Biophysical Research Communications 346 (2006) 45-50

Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor.
Burk O., Arnold K. A., Nussler A. K., Schaeffeler E., Efimova E., Avery B. A., Avery M. A., Fromm M. F. and Eichelbaum M
Mol Pharmacol 67, 1954-65. (2005)

ABCC1/MRP1

Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1)
Holland ML, Allen JD, Arnold JC.
Eur J Pharmacol. 2008 Sep 4;591(1-3):128-31.

Mechanistic study of potentiation of chemotherapy by a haloenol lactone derivative in vitro
Wei Wang, Cindy Q. Xia, Ning Liu, Liang-Shang Gan and Jiang Zheng
Cancer Chemother Pharmacol (2008) 62:117-122

A novel noninvasive method for assessing glutathione-conjugate efflux systems in the brain.
Okamura T., Kikuchi T., Fukushi K., Arano Y. and Irie T.
Bioorganic & Medicinal Chemistry 15, 3127-3133., (2007)

Transport of Ethinylestradiol Glucuronide and Ethinylestradiol Sulfate by the Multidrug Resistance Proteins MRP1, MRP2, and MRP3.
Chu X.-Y., Huskey S.-E. W., Braun M. P., Sarkadi B., Evans D. C. and Evers R.
Journal of Pharmacology And Experimental Therapeutics 309, 156-164 (2004)

ABCC2/MRP2

Multidrug resistance-associated transporter 2 regulates mucosal inflammation by facilitating the synthesis of hepoxilin A3.
Pazos M, Siccardi D, Mumy KL, Bien JD, Louie S, Shi HN, Gronert K, Mrsny RJ, McCormick BA.
J Immunol. 2008 Dec 1;181(11):8044-52.

OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, Ikeda T.
Drug Metab Dispos. 2006 May;34(5):862-9.

Mechanism of active renal tubular efflux of tenofovir.
Ray A. S., Cihlar T., Robinson K. L., Tong L., Vela J. E., Fuller M. D., Wieman L. M., Eisenberg E. J. and Rhodes G. R.
Antimicrob Agents Chemother 50, 3297-304. (2006)

Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport.
Yamazaki M., Li B., Louie S. W., Pudvah N. T., Stocco R., Wong W., Abramovitz M., Demartis A., Laufer R., Hochman J. H., Prueksaritanont T. and Lin J. H.
Xenobiotica 35, 737-53. (2005)

ABCC3/MRP3

ABCC4/MRP4

ATP-dependent transport of leukotrienes B4 and C4 by the multidrug resistance protein ABCC4 (MRP4).
Rius M, Hummel-Eisenbeiss J, Keppler D
J Pharmacol Exp Ther. 2008 Jan;324(1):86-94

ABCG2/BCRP

The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids.
Holland ML, Lau DT, Allen JD, Arnold JC.
Br J Pharmacol. 2007 Nov;152(5):815-24.

Interactions between ABC-transport proteins and the secondary Fusarium metabolites enniatin and beauvericin.
Dornetshuber R, Heffeter P, Sulyok M, Schumacher R, Chiba P, Kopp S, Koellensperger G, Micksche M, Lemmens-Gruber R, Berger W.
Mol Nutr Food Res. 2009 Jul;53(7):904-20.

Interactions of cyclosporin a with breast cancer resistance protein.
Xia C. Q., Liu N., Miwa G. T. and Gan L. S.
Drug Metab Dispos 35, 576-82. (2007)

ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein.
Huang L., Wang Y. and Grimm S.
Drug Metab Dispos 34, 738-42. (2006)

Flavonoid structure-activity studies identify 6-prenyichrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.
Ahmed-Belkacem A., Pozza A., Munoz-Martinez F., Bates S. E., Castanys S., Gamarro F., Di Pietro A. and Perez-Victoria J. M.
Cancer Research 65, 4852-4860. (2005)

BSEP

Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.
Feng B, Xu JJ, Bi YA, Mireles R, Davidson R, Duignan DB, Campbell S, Kostrubsky VE, Dunn MC, Smith AR, Wang HF.
Toxicol Sci. 2009 Apr;108(2):492-500.

Inhibition of Hepatobiliary Transport as a Predictive Method for Clinical Hepatotoxicity of Nefazodone.
Seva E. Kostrubsky, Stephen C. Strom, Amit S. Kalgutkar, Shaila Kulkarni, James Atherton, Rouchelle Mireles, Bo Feng, Raylene Kubik, Janean Hanson, Ellen Urda, and Abdul E. Mutlib
TOXICOLOGICAL SCIENCES 90(2), 451-459 (2006)

MultiDrugQuant™ assay kit

P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement
Manthena V.S. Varma, Yasvanth Ashokraj, Chinmoy S. Dey, Ramesh Panchagnula
Pharmacological Research 48 (2003) 347-359